Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplemental Figure 1

A

Progression Free Survival (PFS) Assessed by Investigator Site (mITT)
Subgroup Triple Negative Receptor

OPT-822	28	26	15	12	10	9	8	8	8	5	5	5	4	3
PBS	17	14	8	8	6	5	3	3	3	3	3	2	1	1

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

J Immunother Cancer

B

Progression Free Survival (PFS) Assessed by Investigator Site (mITT)
Subgroup ER and/or PR Positive Plus HER-2 Negative

OPT-822	161	156	127	110	91	81	71	61	54	48	42	34	25	19
PBS	84	77	67	60	53	46	36	32	25	21	13	11	9	6

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

C Progression Free Survival (PFS) Assessed by Investigator Site (mITT)
Subgroup HER-2 Positive

OPT-822	35	30	18	18	12	9	8	7	6	5	4	4	3	2
PBS	23	22	14	10	8	6	5	5	4	4	4	4	3	3